Rajni Mehta, MPH
Associate Director Rapid Case Ascertainment Cancer Center; Director, Rapid Case Ascertainment Shared Resource
Research & Publications
Biography
News
Coauthors
Selected Publications
- Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination toolZhang Y, Mezzacappa C, Shen L, Ivatorov A, Petukhova-Greenstein A, Mehta R, Ciarleglio M, Deng Y, Levin W, Steinhardt S, Connery D, Pineau M, Onyiuke I, Taylor C, Rose M, Taddei T. Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool. PLOS Digital Health 2022, 1: e0000080. PMID: 36812575, PMCID: PMC9931271, DOI: 10.1371/journal.pdig.0000080.
- SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of DecompensationKaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.
- 351 – Cancer Tracking System Improves Timeliness of Liver Cancer Care At a Veterans HospitalZhang Y, Mehta R, Taddei T. 351 – Cancer Tracking System Improves Timeliness of Liver Cancer Care At a Veterans Hospital. Gastroenterology 2019, 156: s-1192. DOI: 10.1016/s0016-5085(19)39956-1.
- Implementation of a Population-Based Cirrhosis Identification and Management SystemKanwal F, Mapaskhi S, Smith D, Taddei T, Hussain K, Madu S, Duong N, White D, Cao Y, Mehta R, El-Serag H, Asch S, Midboe A. Implementation of a Population-Based Cirrhosis Identification and Management System. Clinical Gastroenterology And Hepatology 2018, 16: 1182-1186.e2. PMID: 29803805, PMCID: PMC7185902, DOI: 10.1016/j.cgh.2018.01.041.
- Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity MatchingKaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.
- Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinomaKaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.
- Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional StudyReiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal Of Clinical Oncology 2017, 35: jco.2017.73.824. PMID: 28872925, PMCID: PMC5662845, DOI: 10.1200/jco.2017.73.8245.
- Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United StatesKaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH, Group V. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clinical Gastroenterology And Hepatology 2017, 16: 106-114.e5. PMID: 28756056, PMCID: PMC5735018, DOI: 10.1016/j.cgh.2017.07.024.
- Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.
- Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and MortalitySerper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.
- Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosisGoldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M, Pocha C, Valderrama A, Kaplan DE. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology 2017, 65: 864-874. PMID: 27531119, DOI: 10.1002/hep.28765.
- Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.
- Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.
- Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with CirrhosisKaplan DE, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Taddei T, for the VOCAL Study Group. Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Digestive Diseases And Sciences 2016, 61: 3309-3320. PMID: 27405990, PMCID: PMC5067291, DOI: 10.1007/s10620-016-4239-6.
- Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare DatabaseKaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Knott A, Pedrosa M, Pocha C, Mehta R, Duggal M, Skanderson M, Valderrama A, Taddei TH, Group V. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clinical Gastroenterology And Hepatology 2015, 13: 2333-2341.e6. PMID: 26188137, PMCID: PMC4655141, DOI: 10.1016/j.cgh.2015.07.010.
- Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010.Kaplan D, Taddei T, Aytaman A, Hunt K, Knott A, Dieperink E, Baytarian M, Fox R, Pedrosa M, D'Addeo K, Dai F, Mehta R, Duggal M, Pocha C, Skanderson M, Valderrama A. Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010. Journal Of Clinical Oncology 2015, 33: 243-243. DOI: 10.1200/jco.2015.33.3_suppl.243.
- Mo1036 Development and Validation of a Virtual Child-Turcotte-Pugh Score to Assess Liver Disease Severity in an Administrative Healthcare DatabaseKaplan D, Taddei T, Skanderson M, Pocha C, Pedrosa M, Mehta R, Knott A, Hunt K, Fox R, Duggal M, Dai F, D K, Baytarian M, Valderrama A, Aytaman A. Mo1036 Development and Validation of a Virtual Child-Turcotte-Pugh Score to Assess Liver Disease Severity in an Administrative Healthcare Database. Gastroenterology 2014, 146: s-992. DOI: 10.1016/s0016-5085(14)63605-2.
- Mo1059 Interim Analysis of HCC Screening and Survival in 1131 Veterans Diagnosed With HCC From 2008-2010Taddei T, Kaplan D, Aytaman A, Baytarian M, D K, Dai F, Duggal M, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Skanderson M. Mo1059 Interim Analysis of HCC Screening and Survival in 1131 Veterans Diagnosed With HCC From 2008-2010. Gastroenterology 2014, 146: s-998. DOI: 10.1016/s0016-5085(14)63627-1.
Clinical Trials
| Conditions | Study Title |
|---|---|
| Lung | Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer |